RT Journal Article
T1 Circulating regulatory T cells from breast cancer patients in response to neoadjuvant chemotherapy
A1 Sanchez-Margalet, Victor
A1 Barco-Sanchez, Antonio
A1 Vdarino-Garcia, Teresa
A1 Jimenez-Corteguna, Carlos
A1 Perez-Perez, Antonio
A1 Henao-Cartusco, Fernando
A1 Virizuela-Echaburu, Juan A.
A1 Nogales-Fernandez, Esteban
A1 Alamo-de la Gala, Maria C.
A1 Lobo-Acosta, Maria A.
A1 Palazon-Carrion, Natalia
A1 Nieto, Adoracion
A1 de la Cruz-Merino, Luis
K1 Breast cancer
K1 neoadjuvant therapy
K1 lymphocyte subpopulations
K1 regulatory T cells (Tregs)
K1 effector T lymphocytes
K1 Peripheral-blood
K1 Identification
K1 Progression
AB Background: Immune escape of tumor cells is a new hallmark of cancer in general, and breast cancer, in particular. Previous studies have demonstrated that the immunological profile in peripheral blood may be a prognostic and/or predictive biomarker in breast cancer. Thus, higher number of regulatory T cells (Tregs) in blood from patients with breast cancer has been reported in relation to normal donors. In the present study, we planned to evaluate the changes in different cell populations in peripheral blood: neutrophils, monocytes and lymphocytes, as well as lymphocyte subpopulations [natural killer (NK), B lymphocytes, T lymphocytes, both CD4(+) and CD8(+), and Tregs] from patients with local breast cancer (both Her2(+) and Her2(-)), before, during and after neoadjuvant chemotherapy.Methods: We have employed flow cytometry for the cell analysis of fresh samples obtained before and whilst the neoadjuvant treatment was accomplished. We have studied 50 successive patients from the Breast Cancer Unit of the Virgen Macarena University Hospital during 2 years.Results: Neoadjuvant chemotherapy induced a significant reduction in B cells, especially in Her2(-) patients, and a reduction in NK cells. CD4(+) T cells decreased, whereas CD8(+) cells only decreased in Her2(-) patients. Tregs were also diminished, especially in Her2(+) patients, in response to treatment. Thus, higher CD8/Treg ratio was observed in Her2(+) patients. A higher percentage of Her2(+) patients (66.6%) achieved complete response than Her2(-) patients (27.5%). Monocytes and neutrophils were not changed in peripheral blood.Conclusions: Even though the decrease in B cells and NK cells in response to chemotherapy may be deleterious in the neoadjuvant treatment of breast cancer, the decrease in Tregs and CD4 T cells, but not CD8 T cells, increasing the CD8/Treg ratio, especially in Her2(+) patients, may reveal a new tool to monitor the immune response in breast cancer treated with chemotherapy in the neoadjuvant setting.
PB Ame publ co
SN 2218-676X
YR 2019
FD 2019-02-01
LK http://hdl.handle.net/10668/19475
UL http://hdl.handle.net/10668/19475
LA en
DS RISalud
RD Apr 14, 2025